ABSTRACT
Pelvic radiotherapy (RT) often results in toxicity to the gastrointestinal tract and clinical trials have demonstrated a potential benefit of dietary supplements in alleviating acute effects. However, no prophylactic agents have been approved to date for relief of gastrointestinal side-effects caused by pelvic radiation. This systematic review and meta-analysis were undertaken with the aim of evaluating the efficacy of a number of dietary supplement interventions in preventing or alleviating symptoms of gastrointestinal toxicity in patients undergoing RT for a range of common pelvic malignancies. The search protocol was prospectively submitted to PROSPERO at the University of York. CENTRAL, MEDLINE, EMBASE, and ClinicalTrials.gov were searched up to June 2020 for randomised controlled clinical trials. Interventions included four supplement categories: biotics, amino acids, poly-unsaturated fatty acids and polyphenols. Efficacy was determined with reference to outcomes based on symptoms of acute gastrointestinal toxicity, including diarrhoea, nausea, vomiting, flatulence/bloating, bowel movement frequency, tenesmus and rectal bleeding. Twenty-three randomised controlled trials (1919 patients) were identified in this review. Compared with placebo, probiotics (RR=0.71; 95% CI: 0.52 to 0.99), synbiotics (RR=0.45; 95% CI: 0.28 to 0.73) and polyphenols (RR=0.30; 95% CI: 0.13 to 0.70) were significantly associated with a lower risk of diarrhoea. Biotic supplements also reduced the risk of moderate to severe diarrhoea (RR=0.49; 95% CI: 0.36 to 0.67) and the need for anti-diarrhoeal medication (RR=0.64; 95%CI: 0.44 to 0.92). In contrast, amino acid supplements had no effect on acute symptoms (RR=1.05; 95% CI:0.86 to 1.29). There was a non-significant trend for reduction in nausea and mean bowel movements per day using dietary supplements. Biotic supplements, especially probiotics and synbiotics, reduce acute symptoms of gastrointestinal toxicity in patients undergoing pelvic radiotherapy.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
N/A
Funding Statement
This work was funded by Cancer Research UK Programme grant C5255/A23755. Chee Kin Then's DPhil is funded by the Clarendon Fund, Balliol College and CRUK. The funding body had no role in the design of the study, collection, analysis, interpretation of data or in writing the manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
N/A
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Author responsible for statistical analysis name & email address Dr. Christiana Kartsonaki. Email: christiana.kartsonaki{at}dph.ox.ac.uk
Funding statement This work was funded by Cancer Research UK Programme grant C5255/A23755. Chee Kin Then’s DPhil is funded by the Clarendon Fund, Balliol College and CRUK. The funding body had no role in the design of the study, collection, analysis, interpretation of data or in writing the manuscript.
Data availability statement for this work N/A
Conflict of interest None
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.